Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from SanBio Co ( (JP:4592) ) is now available.
SanBio Co., Ltd. has revised its consolidated earnings forecast for the fiscal year ending January 2026, indicating a greater than expected loss. The revision is attributed to increased manufacturing expenses for future clinical trials and the launch of AKUUGO following regulatory approval, as well as foreign exchange losses and deferred tax liabilities impacting net income.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2100.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development of regenerative cell medicines. The company is known for its innovative therapies aimed at treating neurological disorders and other medical conditions.
Average Trading Volume: 2,887,422
Technical Sentiment Signal: Buy
Current Market Cap: Yen170.1B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.